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Background: Sorafenib is an orally administered multikinase inhibitor with antiangiogenic and antiproliferative
properties. The results of large clinical trials demonstrate that sorafenib prolongs survival and the time to
progression of patients with advanced hepatocellular carcinoma (HCC). The aim of the present study was to
determine the outcomes of such patients who were routinely treated with sorafenib at multi-institutions in Korea,
in contrast to formal clinical trials.
Methods: Between August 2007 and March 2012, patients with advanced HCC in seven referral medical centers
in Daejeon-Chungcheong Province of Korea were retrospectively enrolled to evaluate treatment response, survival,
and tolerability following administration of sorafenib. The treatment response was assessed in accordance with the
Response Evaluation Criteria in Solid Tumor 1.1 guidelines.
Results: Among 116 patients, 66 (57%) had undergone treatment for HCC, and 77 (66%) were accompanied with
Child-Pugh A cirrhosis. The median duration of sorafenib treatment was 67 days (range 14–452 days). Median
overall survival and median time to progression were 141 days and 90 days, respectively. Complete response,
partial response, and stable disease were achieved for 0%, 2%, and 29% of patients, respectively. Overall median
survival, but not the median time to progression, was significantly shorter for patients with Child-Pugh B cirrhosis
compared with those with Child-Pugh A cirrhosis (64 days vs 168 days, P = 0.004). Child-Pugh B cirrhosis (P = 0.024)
and a high level of serum alpha-fetoprotein (P = 0.039) were independent risk factors for poor overall survival.
Thirty-nine (34%) patients experienced grade 3/4 adverse events such as hand-foot skin reactions and diarrhea that
required dose adjustment.
Conclusions: The clinical outcomes of sorafenib-treated patients with advanced HCC were comparable to those
reported by formal clinical trial conducted in the Asia-Pacific region. Underlying hepatic dysfunction was the most
important risk factor for shorter survival.
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Hepatocellular carcinoma (HCC) is the fifth most common
malignancy worldwide and patient’s outcomes are generally
poor [1,2]. Although potentially curable at an early stage,
only 30-40% of patients with HCC at the time of diagnosis
are eligible for curative treatments such as liver trans-
plantation, tumor resection, or percutaneous radiofre-
quency ablation (RFA), and the majority of patients
are obligated to undergo noncurative treatments such as
transcatheter arterial chemoembolization (TACE) [3]. The
role of systemic chemotherapy in treating patients with
HCC at an advanced stage beyond these standard treat-
ments was addressed by a few phase II/III clinical trials
[4-6]. The poor outcomes of the majority of patients with
HCC are presumably related to the aggressive behavior
of HCC that causes progression to intrahepatic spread,
invasion of large vessels, and distant metastasis.
Sorafenib is an orally administered drug that inhibits
multiple protein kinases, including two transmembrane
receptors as well as intracellular tyrosine and serine-
threonine kinases, which together mediate tumor cell
proliferation and angiogenesis [7,8]. During 2008–2009,
the Sorafenib HCC Assessment Randomized Protocol
(SHARP) and Asia-Pacific trials, which were international
randomized controlled trials, showed a limited clinical
benefit and acceptable safety profile of sorafenib treatment
for patients with advanced HCC [9,10]. Although statisti-
cally significant, the increase in patients’ survival of approxi-
mately 2–3 months is disappointing to patients and their
families. Further, radiological assessment revealed that the
sum of complete and partial response rates was <5% in
both trials. Unfortunately, few routine clinical data are
available on the effects of sorafenib on patients with
HCC in advanced stages with major vessel invasion
or extrahepatic spread.
A greater knowledge of the efficacy and safety of sorafenib
for treating patients with advanced HCC is required to
develop treatment guidelines and to facilitate an informed
decision-making process for patients with poor hepatic
functional reserve or advanced liver cirrhosis [11,12]. The
aims of the present study were to evaluate the treatment
patterns, outcomes, and safety of sorafenib for routine treat-
ment of Korean patients with advanced HCC with hepatic
decompensation and compensated liver function.
Methods
Study population
We identified 146 patients with unresectable HCC who
were treated with sorafenib between August 2007 and
March 2012 in seven university referral hospitals located
in Daejeon Metropolitan City and Chungcheong
Province of Korea as follows: Dankook University
Hospital, Soonchunhyang University Hospital, Chungnam
National University Hospital, Konyang University Hospital,Chungbuk National University Hospital, Eulji University
Hospital, and Konkuk University Hospital. The com-
puterized medical records of these patients were retro-
spectively reviewed. After review, 30 patients were
excluded as follows: 14 patients received <2 weeks of
sorafenib treatment; seven patients with Child-Pugh C
cirrhosis; five patients with no follow-up after the first visit
for sorafenib treatment; three patients without adequate
medical information, including the dose of sorafenib; and
one patient without any evidence to support the diagnosis
of HCC. The final 116 patients were assessed for treatment
response, survival, and adverse effects. HCC was diagnosed
according to either histologic or radiologic findings.
Typical radiologic findings were as follows: a wash-out
hepatic nodule on the portal or delayed hepatic venous
phase following a hypervascular enhancing hepatic nodule
on the arterial phase of imaging modalities such as
dynamic computed tomography or magnetic resonance
imaging with evidence of chronic liver disease regardless
of the serum level of alpha-fetoprotein (AFP) [13]. HCC
was considered unresectable according to the criteria as
follows: extensive bilobar involvement of the liver due to
single or multiple tumors; insufficient hepatic functional
reserve (>15% of preoperative 15-min retention rate of
indocyanine green); tumor invasion of major vessels such
as portal or hepatic veins or the inferior vena cava; or an
extrahepatic spread [14]. We conducted a review of
patients’ medical records and collected data on the
characteristics as follows: patient demographics, cause
of liver disease, Eastern Cooperative Oncology Group
(ECOG) performance status, hepatic functional reserve,
previous treatments, and baseline tumor characteristics.
The enrolled patients granted informed consent to evaluate
their treatment of HCC. The Institutional Review Boards
for Human Research of Dankook University Hospital,
Soonchunhyang University Hospital, Chungnam National
University Hospital, Konyang University Hospital, Chung-
buk National University Hospital, Eulji University Hospital,
and Konkuk University Hospital approved this study,
which followed the ethical principles of the Declaration of
Helsinki.
Clinical outcomes and assessments
The primary endpoint of the study was overall survival,
which was calculated from the date of sorafenib adminis-
tration to the date of death from any cause. Secondary
endpoints included the disease control rate with tumor
response, time to radiological progression, and drug
safety/tolerability. Tumor response was assessed according
to the Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1 [15]. The disease control rate was
defined as the percentage of patients with the best rating
of complete response, partial response, or stable disease
according to RECIST criteria that was maintained for at
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The time to radiological progression was defined as the
time from sorafenib administration to tumor progression
according to RECIST criteria. Drug safety and tolerability
were classified in accordance with the National Cancer
Institute Common Terminology Criteria for Adverse
Events (NCI-CTCAE) version 3.0 [16].
Statistical analysis
The data were expressed as the median (range) and the
number (percentage). The overall survival and cumulative
progression rates of HCC were evaluated using the
Kaplan–Meier method with a log-rank test to determine
the significance of the differences. Multivariate analysis
performed to identify independent risk factors for overall
survival using the Cox proportional hazard model after
univariate analysis. P < 0.05 was considered statistically
significant. All the analyses were performed using SPSS
14.0 software (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
The baseline clinical characteristics of 116 patients with
HCC who were treated with sorafenib are summarized
in Table 1. The median age (range) of the patients was
56 (34–82) years, and 93 patients (80%) were male.
Hepatitis B virus (HBV) was the most frequent cause of
liver disease, followed in descending order by alcohol,
hepatitis C virus (HCV), and others. Eighty-eight patientsTable 1 Baseline characteristics of patients
Characteristics Subjects (n = 116)
Age, years* 56 (34–82)
Male gender, n (%) 93 (80)
Etiology, n (%)
HBV/HCV/alcohol/others 79/6/18/13 (68/5/16/11)
Child-Pugh classification, n (%)
A/B 77/39 (66/34)
ECOG performance status, n (%)
0-1/2 88/28 (76/24)
History of prior treatment, n (%) 66 (57)
Modified UICC stage, n (%)
II/III/IVa/IVb 2/26/30/58 (2/22/26/50)
BCLC stage, n (%)
B/C/D 19/93/4(16/80/4)
AFP, ng/dL* 124 (1–150000)
Macrovascular invasion, n (%) 64 (55)
Extrahepatic metastasis, n (%) 54 (46)
*median (range).
Abbreviations: HBV hepatitis B virus, HCV hepatitis C virus, ECOG Eastern
Cooperative Oncology Group, UICC International Union Against Cancer,
BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein.(76%) had an ECOG performance status score of 0 or 1,
77 patients (66%) had Child-Pugh A cirrhosis, and 93
patients (80%) had Barcelona Clinic Liver Cancer (BCLC)
advanced-stage C. The proportion of patients with
macrovascular invasion or extrahepatic metastasis was
55% or 46%, respectively. Sixty-six patients (57%) had
undergone other treatments for HCC before receiving
sorafenib, and the previous treatments and sessions are
summarized in Table 2. TACE was the most frequent
single treatment before administration of sorafenib.
Surgical resection or RFA followed by TACE were the
most frequent combined treatments. Radiological tumor
progression before sorafenib treatment was identified in
all study subjects, and the tumors of 34 patients (29%)
were upstaged according to the modified International
Union Against Cancer (UICC) staging system. The
median follow-up period (range) after sorafenib treatment
was 88 (21–1545) days.
Treatment outcomes
Eighty-three (72%) patients died by the end of the follow-up
period. Median overall survival was 141 (14–1581) days,
and survival rates at 6, 12, and 18 months were 47%, 21%,
and 11%, respectively (Figure 1A). The median follow-up
period was 118 (28–1,581) days for 94 patients treated with
sorafenib for at least 4 weeks who were administered a
follow-up radiological evaluation and were available for
assessment of their radiological response. The radiological
responses of these patients were as follows (Table 3): 0 with
a complete response; 2 (2%) with a partial response; 28
(29%) with stable disease; and 64 (69%) with progressive
disease. The disease control rate was 21.9%. The median
time to radiological progression of 64 patients withTable 2 Treatment modalities before sorafenib therapy
Treatment modalities Subjects (n = 66)
Single treatment, n (%) 40 (61)
TACE 35 (54)
Surgery 4 (6)
Radiation therapy 1 (1)
Multidisciplinary treatment, n (%) 26 (39)
Surgery followed by TACE 11 (17)
RFA followed by TACE 8 (12)
TACE and radiation therapy 4 (6)
RFA followed by TACE and radiation therapy 2 (3)
TACE followed by systemic chemotherapy 1 (1)
Treatment session before sorafenib, n (%)
One 14 (21)
Two 10 (15)
Three or more 42 (64)
Abbreviations: TACE transcatheter arterial chemoembolization,
RFA radiofrequency ablation.
Figure 1 Probability of overall survival (A) and the time to tumor progression (B). The median overall survival was 141 days, and the
survival rates at 6, 12, and 18 months were 47%, 21%, and 11%, respectively. The median time to tumor progression was 90 days.
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The median overall survival of the HCC patients with
Child-Pugh A cirrhosis was significantly longer compared
with that of HCC patients with Child-Pugh B cirrhosis
(186 vs 64 days, P = 0.004) (Figure 2A), although the
median time to tumor progression did not differ between
the groups (104 vs 63 days, P = 0.154) (Figure 2B).
Prognostic factors for overall survival and tumor
progression
Multivariate analysis revealed that Child-Pugh B cirrho-
sis (P = 0.024) and a serum level of AFP >200 ng/mL
(P = 0.039) were independent prognostic factors for
overall survival (Table 4). However, none of the clinical
factors was associated with the time to tumor progression.
Tolerability and safety of treatment
The median period of sorafenib treatment was 67 (14–452)
days, and the median dose of sorafenib was 700 (105–800)
mg per day. Table 5 shows drug-related adverse events and
severe toxicity that each patient experienced predominantly
according to liver function. Seventy-eight (67.2%) patientsTable 3 Responses to sorafenib treatment
N = 94
Complete response 0 (0)
Partial response 2 (2)
Stable disease 28 (29)
Progressive disease 64 (69)
DCR (95% CI) 21.9% (23.7–42.8)
Abbreviations: DCR disease control rate, CI confidence interval.experienced drug-related adverse events such as hand-foot
skin reaction (20%), diarrhea (16%), nausea (6%), anorexia
(5%), fatigue (7%), or rash/desquamation (13%). Grade 3/4
toxicities occurred in 39 (33.6%) patients, which required a
reduction in sorafenib dose to maintain treatment.
However, the occurrence of grade 3/4 toxicities did
not differ between patients with Child-Pugh A or B
cirrhosis. Tumor progression was the most frequent cause
of discontinuation of sorafenib treatment, followed by
drug-related adverse events, hepatic failure, and an
unacceptable economic burden, in decreasing order.
Discussion
Until the advent of sorafenib, no systemic chemotherapy
regimen improved the survival of patients with advanced
HCC compared with those who received the best
supportive care alone [17,18]. Although many clinical
trials used several agents and combinations of these
drugs, only sorafenib was approved by many countries for
the treatment of patients with unresectable HCC, and
sorafenib is now incorporated into practice guidelines
[19-21]. Although sorafenib was the first agent to improve
the overall survival of these patients, the therapeutic
outcomes remain limited and unsatisfactory, even in
well-designed randomized controlled trials. Therefore,
This study was intended to assess the efficacy of sorafenib
in actual clinical practice, in contrast to a clinical trial.
The median overall survival of approximately 4.7 months
of the patients described here is inconsistent with the data
of the SHARP [9] and Asia-Pacific trials [10]. When the
present study commenced, we enrolled more patients with
Child-Pugh B cirrhosis and ECOG performance status 2
Figure 2 Probability of overall survival (A) and the time to progression (B) according to Child-Pugh classification of cirrhosis. The
median overall survival of the HCC patients with Child-Pugh A cirrhosis was significantly longer compared with that of the HCC patients with
Child-Pugh B cirrhosis (186 days vs 64 days, P = 0.004), although the median time to tumor progression did not differ between the two groups
(104 days vs 63 days, P = 0.154).
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different characteristics of patients indicate that the
patients had decompensated hepatic reserve function
and a poorer prognosis compared with those of the
SHARP [9] or Asia-Pacific trials [10]. To reconcile
our expectation with the findings of those trials, the
survival rate of patients with Child-Pugh B cirrhosis
was significantly lower compared with those diagnosed
with Child-Pugh A cirrhosis. However, because it is uncer-
tain whether the data may be explained by the effects of
sorafenib or those of innate hepatic progressive disease,
these results should be interpreted with caution.
The median time to progression of 3 months observed
here was comparable with that reported by the Asia-Pacific
trial [10] but not by the SHARP trial [9]. We believe thatTable 4 Univariate and multivariate analysis of risk factors fo
Factors Univariate
OR (95% CI)*
Age (>60 years) 0.77 (0.49–1.22)
Gender (male) 1.47 (0.81–2.67)
ECOG performance status (2) 1.13 (0.67–1.89)
Etiology (HBV-related) 1.26 (0.79–1.98)
Child-Pugh classification ( B) 1.93 (1.22–3.03)
History of prior treatment (yes) 0.68 (0.44–1.04)
AFP (>200 ng/mL) 1.63 (1.01–2.64)
Macrovascular invasion (yes) 1.56 (0.99–2.45)
Extrahepatic metastasis (yes) 1.21 (0.78–1.89)
*odds ratio (95% confidence interval).
Abbreviations: ECOG Eastern Cooperative Oncology Group, HBV hepatitis B virus, AFPthese results can be explained by an epidemiological simi-
larity of the composition of the study populations enrolled
in the present study and the Asia-Pacific trial [10], despite
the difference in the hepatic reserve function of patients
analyzed in each study. The distribution of endemic hepa-
titis virus differs among geographical regions. For example,
68% of the patients enrolled here had chronic HBV infec-
tion compared with 73% and 18% of those enrolled in the
Asia-Pacific and SHARP trials, respectively. In contrast,
the proportions of patients with chronic HCV infection re-
cruited in our study and the Asia-Pacific trial were 5% and
8.4%, respectively, while that of the SHARP trial was 28%.
In contrast to the subanalysis results of overall survival,
the time to tumor progression did not differ between
patients with HCC with Child-Pugh A or B cirrhosis. Thisr overall survival
Multivariate
P OR (95% CI)* P
0.274
0.2 1.96 (0.96–4.01) 0.062
0.629
0.32
0.004 1.84 (1.08–3.13) 0.024
0.08 0.78 (0.46–1.33) 0.376
0.047 1.76 (1.02–3.02) 0.039
0.054 1.96 (0.96–4.01) 0.062
0.383
alpha-fetoprotein.
Table 5 Incidence of drug-related adverse events
according to liver function
AE All grades
(n = 78)
Grade 3/4 (n = 39)
Child-Pugh A Child-Pugh B P
HFSR 23 10 4 0.340
Diarrhea 19 6 4 0.655
Nausea 7 1 0 0.475
Anorexia 6 4 1 0.510
Fatigue 8 2 1 0.991
Rash/desquamation 15 3 3 0.383
Abbreviations: AE adverse event, HFSR hand-foot skin reaction.
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on tumor progression of patients treated with sorafenib
may be insignificant. Although the disease control rate of
our study was lower compared with those of the SHARP
and Asia-Pacific trials, the result should be considered
cautiously, because patients with HBV-related HCC
survived for a significantly shorter time compared
with those with HCV-associated HCC, and sorafenib
may be less effective in HBV-positive patients with HCC
[22]. Therefore, we suggest that a clinical assessment of
sorafenib should be conducted more carefully for patients
with advanced HCC in areas with endemic HBV infection.
Although sorafenib was originally approved as first-line
treatment for unresectable HCC, it was administered as
second-line treatment to more than half of the subjects in
the present study after the tumor progression or recur-
rence following the initial treatments. In previous studies,
prior treatment was associated with shorter overall survival
rate but was not an independent risk factor for survival
[23-25]. However, in the present study, baseline tumor
characteristics and liver function were not significantly
different between patients with or without prior treatment,
and the overall survival of patients did not vary signifi-
cantly depending on whether they received prior treat-
ment. Taken together, these findings suggest that sorafenib
is equally as effective as second-line treatment compared
with its use as first-line treatment if patients have sufficient
hepatic reserve. In the present study, Child-Pugh classifica-
tion and serum AFP level, among several clinical parame-
ters, were identified as independent predictors of overall
survival. The results of other studies indicate that tumor
characteristics (e.g. size, differentiation, vascular invasion,
and extrahepatic metastasis) and patients’ performance
status as well as liver function should be taken into
account as prognostic determinants [26-28].
The frequency of drug-related adverse events noted in
this study differed from those reported by other studies,
although the types of adverse events were similar. In
general, sorafenib-related adverse events occur more
often in populations of Eastern countries compared withthose of Western countries. The overall incidence of
drug-related adverse events in this study was comparable
to that of the Asia-Pacific trial, not the SHARP trial. The
epidemiological differences associated with ethnicity may
affect the development of drug-related adverse events,
although this is unconfirmed. Grade 3/4 drug-related
adverse events made it necessary to adjust the dose of
sorafenib administered to 33.6% of patients in the present
study. Hand-foot skin reactions and diarrhea were the
major adverse events. However, similar to the results of
other studies [23,25,29], these grade 3/4 toxicities did not
differ with respect to reserve liver function.
Sorafenib was generally tolerated by patients with
Child-Pugh class B disease, although their daily average
dose of sorafenib was higher than that prescribed for
patients with Child-Pugh class A. There was no significant
difference in sorafenib tolerability or time to progression
between the Child-Pugh class A and B groups, although
overall survival was longer in the former group. In the
present study, approximately two-thirds of the patients
discontinued sorafenib treatment because of tumor
progression or adverse events, each a key weakness of
sorafenib treatment.
We note certain limitations of the present study. First,
this was a retrospective study of patients’ medical
records. Selection bias could not be avoided to some
extent, and the information on drug compliance and
adverse events may be insufficient. Next, this was a
protocol-free, guideline-based study of routine clinical
practice, in contrast to a formally designed and control
study. Therefore, the possibility exists that the results were
underestimated. Finally, this was not a comparative study.
The lack of a control arm has the inherent limitation of
analyzing clinical data independently from the results of
prior studies.
Conclusions
Here, we show that the outcomes of sorafenib treatment
of Korean patients with advanced HCC in actual clinical
practice was comparable to other studies conducted in
the Asia-Pacific region in terms of tolerability and safety
profiles. The median overall survival of patients with
HCC with Child-Pugh A cirrhosis was significantly longer
compared with that of HCC patients with Child-Pugh B
cirrhosis, although the median time to progression did not
differ between the groups. Further studies should be
aimed to maximize the effect of sorafenib by selecting
patients who will benefit the most.
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